Across TCGA pan-cancer cohorts, HMGXB3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HMGXB3 data layer compared with 30 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HMGXB3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HMGXB3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.
CCRCC, LSCC, and HNSC are the cancer types where HMGXB3 mass-spec protein most reproducibly stratifies survival.